{ "schemaVersion": "deck-intelligence.v1", "id": "019de073-f2d4-7758-94ad-33c5441d40e0", "slug": "ecbf51e8e3db999397a90a848caaf022", "title": "BioAtla | Investor Presentation Deck | 40 slides", "subtitle": "BioAtla · 2022-11", "author": "BioAtla", "date": "2022-11-01 00:00:00", "pageCount": 40, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de073-f2d4-7758-94ad-33c5441d40e0", "slug": "ecbf51e8e3db999397a90a848caaf022", "title": "BioAtla | Investor Presentation Deck | 40 slides", "rawTitle": "BioAtla | Investor Presentation Deck | 40 slides", "authorId": "bioatla", "authorName": "BioAtla", "authorDisplay": "BioAtla", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2022-11__bioatla__investor-pres__ecbf51e8.pdf", "sourceUrl": "https://www.slidebook.io/company/bioatla/presentation/ecbf51e8e3db999397a90a848caaf022/", "sourceDate": "2022-11-15 00:00:00", "presentationDate": "2022-11-01 00:00:00", "ingestedAt": "2026-04-30 22:13:08.53783+00", "status": "ready", "pageCount": 40, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2022-11__bioatla__investor-pres__ecbf51e8", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 40, "pagesIndexed": 40, "pagesWithImages": 40, "pagesWithMetadata": 40, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 207, "chartCount": 16, "metricSlides": 0, "toolMatches": 14, "documentToolMatches": 0, "frameworkMatches": 11, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with a clear problem statement, solution, and market opportunity", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:28:04.637337+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 3, "name": "Problem", "beatId": "d534b082-76eb-47f4-b640-8a4988410764", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents the problem of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Solution", "beatId": "f23101c4-32a8-4152-930d-edd35c1a515e", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents BioAtla's CAB technology and its potential to enhance clinical outcomes", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "555802a6-f553-4397-9934-b688b1464c26", "evidence": "The deck presents the limitations of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "objective": "What is the cost of not adopting CABs for cancer therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:28:04.831256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "97b8de81-634d-4b1a-b5f7-6493d56e8add", "evidence": "This slide contains a summary of the company's current status and future plans.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:01.731964+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "0056e777-5567-47af-bd4a-61dc259fa9db", "evidence": "This slide is targeted at investors and partners, showing the company's technology and its applications.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:15:01.904506+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bfea6cec-4f12-4427-81ed-a30caa25eaed", "evidence": "This slide compares different antibody types in a three-column comparison.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:15:02.080559+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7899817c-7689-45bc-86c2-bd387dfc0afa", "evidence": "This slide serves as a divider between sections, focusing on the CAB-AXL-ADC Platform.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:02.216469+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cc797f63-c32c-4402-b60f-fc40d20b5f7d", "evidence": "This slide shows a waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:02.35454+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "09b773e7-c2fb-4dce-93c1-8683ed154e8c", "evidence": "chart/bar-vertical: ORR (%) by patient cohort: NSQ+SQ (36%), All NSQ (42%), NSQ monotherapy (50%), NSQ mono PD-1 Failure (57%), NSQ BA3011 + nivolumab (25%), SQ (0%)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:36:36.219388+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f0f6a059-c21d-467b-af9c-27e08496b7ec", "evidence": "chart/waterfall: Waterfall plot of % change in sum of target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:36:36.29041+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "e9f27a62-e4a4-4938-af0c-d29e84fd6ebf", "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:57:48.048382+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b0d509be-e63f-4ab7-994f-3c2a07941549", "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:57:48.007293+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "61996e84-872f-4056-9bda-3c182221e51f", "evidence": "chart/waterfall: Waterfall plot of tumor shrinkage", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:36:36.358062+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "0959c604-a95b-4595-bb21-1704568041be", "evidence": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:14:57.505202+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cc5bc808-c6df-42f4-afce-74ffcd8de777", "evidence": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:14:57.466583+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "abe9e13d-d8a1-4948-bcba-54719354c2fe", "evidence": "No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is a first-in-class therapy across multiple tumor types", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:14:57.642533+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "db7bc366-f648-4bbc-9263-e9459d39e9f4", "evidence": "This slide serves as an executive summary with key company highlights.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:14:59.192856+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "1dbed918-5905-474c-8c04-3ba636606ba0", "evidence": "Visual split between healthy and cancer cell conditions", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "comparison_frame" }, { "matchId": "4761d4a7-701e-48ab-8089-1f2ac59f8c6d", "evidence": "Horizontal bars representing project timelines across clinical phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "gantt-chart" }, { "matchId": "ea02a069-cd41-4636-bb4f-5f16f4f6d2b7", "evidence": "Hierarchical flow chart mapping study arms to outcomes", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "process" }, { "matchId": "ccfe9b49-4707-4b8b-b9bb-6ed766d33b47", "evidence": "Presents clinical trial safety data in a structured table and bulleted summary format.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "evidence-matrix" }, { "matchId": "4ea6b357-7202-47b7-ba92-38f2187bd062", "evidence": "Quantifies total addressable population and specific sub-segments for a drug candidate.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "market-sizing" }, { "matchId": "621bcb66-5ff1-4438-b622-c7f5165c02b7", "evidence": "Table comparing clinical endpoints of two drug regimens", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "comparison-frame" }, { "matchId": "472d08e7-1180-40a5-aa8c-765a5a10505f", "evidence": "The timeline visualization of trial cohorts functions as a Gantt chart for clinical development.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "gantt-chart" }, { "matchId": "b88141b5-d8d7-45a8-b2e4-eb2c57a0c0d9", "evidence": "The slide contrasts the problem of CRS/toxicity in standard bispecifics with the solution/results of BA3182.", "framework": null, "confidence": 0.85, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "before-after-bridge" }, { "matchId": "9c6f5b16-d8ce-45d2-b83f-f6884e5cd49a", "evidence": "Flowchart showing dose escalation steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "frameworkName": "process" }, { "matchId": "adf2e475-f229-469c-baff-98b6802b4643", "evidence": "The slide maps specific activities (milestones) against a time axis (1H/2H 2022).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "gantt-chart" }, { "matchId": "5bd3611f-c677-45a5-87da-b66e8fc8ec7c", "evidence": "The linked circular diagram suggests a continuous, reinforcing process.", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 12:19:44.121+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "flywheel" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/oxD0Mr-K0fpyLE7QqInNODsXeXmdn5ISO_15n6LSQ1A/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lY2JmNTFlOGUzZGI5OTkzOTdhOTBhODQ4Y2FhZjAyMi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 5, "textChars": 113, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:37.651+00", "seconds": 2.797, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/1", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-1", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.15, "x": 0.05, "y": 0.085 }, "kind": "image", "text": "bioatla", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.651+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "487e1d83-a387-42ae-a87b-e74e7cf9de8f", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.65, "x": 0.35, "y": 0 }, "kind": "image", "text": "Family photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.651+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ef6c5a8-213b-40c8-954f-d33f3a6231c9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.72 }, "kind": "paragraph", "text": "November 2022", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.651+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80c8237f-c239-4bab-a8d6-ae1bc2404866", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.62 }, "kind": "paragraph", "text": "Corporate Presentation", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.651+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9c99d38-4fd6-4117-b4a4-f57f20782d64", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.05, "y": 0.15 }, "kind": "title", "text": "Conditionally Active Biologics: Transforming Cancer Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.651+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5984b76-9c64-41ba-8c81-898abad41973", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/d_rc_4F9BlPXMJfaZGWj-QqQbUuDVqtr3CEp6bLgGIE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lY2JmNTFlOGUzZGI5OTkzOTdhOTBhODQ4Y2FhZjAyMi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/tpK4ULAgG1GVoWGNNj5Dcg9s4u1YelDrzSh6vqgHYgY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lY2JmNTFlOGUzZGI5OTkzOTdhOTBhODQ4Y2FhZjAyMi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/Fhn1-2uItmTIJHn2epTlm2m5UWIQRapl-5OZWWFfXuA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lY2JmNTFlOGUzZGI5OTkzOTdhOTBhODQ4Y2FhZjAyMi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 3, "textChars": 263, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:37.654+00", "seconds": 2.637, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/2", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-2", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.17 }, "kind": "disclaimer", "text": "This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.654+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f4761cc-ee96-405d-9bde-2d0d43a88953", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.1, "x": 0.03, "y": 0.91 }, "kind": "image", "text": "BioAtla logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.654+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8eae5104-57fd-4113-a1ee-be61d1fd8b64", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Important Notices & Disclaimers", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.654+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "065d789e-36bf-4034-b166-560293d373ef", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a connected circle diagram to represent the company's key pillars.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 658, "nDataPoints": 1, "notes": "The slide uses a connected circle diagram to represent the company's key pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:37.899+00", "seconds": 2.828, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/3", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-3", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "Four interconnected circles representing: Proprietary technology, Clinical progress, Pipeline, and Financial position.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "194e5976-547f-434c-bdcd-b28d76627b88", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.3, "y": 0.43 }, "kind": "paragraph", "text": "Two Phase 2 CAB-ADCs, Interim BA3011 Phase 2 data supports advancing to registration studies in multiple sarcoma and NSCLC indications", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f5d23b4-8e1f-40ce-97ff-3134f3a53a76", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.76, "y": 0.43 }, "kind": "paragraph", "text": "Strong cash position, $178.1MM (3Q22) with runway into 2H24, Sufficient through key clinical milestones", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "256485ad-ae45-4e95-ada3-a3a790530958", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.07, "y": 0.43 }, "kind": "paragraph", "text": "Proprietary technology, Broad applicability in solid tumors, Increases therapeutic window", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "729be1dd-b3ff-43fe-811f-17dbbbc212f9", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.53, "y": 0.43 }, "kind": "paragraph", "text": "Diversified pipeline, Near-term clinical readouts for multiple indications, Strategic optionality", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c460d8a6-2cb8-45be-9a7b-c4eb885b52e5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.899+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "441e3af5-13cb-4c7d-8b21-af69f86d5597", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "97b8de81-634d-4b1a-b5f7-6493d56e8add", "evidence": "This slide contains a summary of the company's current status and future plans.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:01.731964+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "d534b082-76eb-47f4-b640-8a4988410764", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents the problem of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "555802a6-f553-4397-9934-b688b1464c26", "evidence": "The deck presents the limitations of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "objective": "What is the cost of not adopting CABs for cancer therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:28:04.831256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "setup", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 13, "componentCount": 3, "textChars": 94, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.515+00", "seconds": 4.052, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/4", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-4", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.92, "x": 0.04, "y": 0.15 }, "kind": "image", "text": "10 headshots of team members", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.515+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "565c2fb5-f282-493e-aa91-8aa625b3ba1c", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.92, "x": 0.04, "y": 0.15 }, "kind": "paragraph", "text": "Names, titles, and company logos for 10 executives.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.515+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fc80ea3-df0c-4e2a-828f-cf63293f2fc1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.23, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Leadership Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.515+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9437f67a-bbf6-42a4-bedf-6d1da92e0fec", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "d534b082-76eb-47f4-b640-8a4988410764", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents the problem of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "555802a6-f553-4397-9934-b688b1464c26", "evidence": "The deck presents the limitations of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "objective": "What is the cost of not adopting CABs for cancer therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:28:04.831256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "resolution", "title": "Uses a visual comparison framework to contrast healthy cells (no binding) vs cancer cells (binding).", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 4, "textChars": 872, "nDataPoints": 0, "notes": "Uses a visual comparison framework to contrast healthy cells (no binding) vs cancer cells (binding).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:38.675+00", "seconds": 3.209, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/5", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-5", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.37, "x": 0.58, "y": 0.25 }, "kind": "image", "text": "Visual comparison of healthy cell membrane (alkaline) vs cancer cell membrane (acidic) showing CAB binding mechanism.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9818e57-68a3-42cf-a33f-c2414e9e8795", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.4, "x": 0.11, "y": 0.28 }, "kind": "list", "text": "BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells. BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells. CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated. CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dabd8106-0107-496f-a5f0-9bdab6944874", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.57, "y": 0.9 }, "kind": "source-note", "text": "Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b28eff8-f89c-40e0-bc78-38aa55b9e724", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Selective and targeted CAB technology widens therapeutic window, thus has the potential to enhance clinical outcomes in multiple tumor types", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fadcef3d-f673-4d2d-8b49-72394886fa49", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "0056e777-5567-47af-bd4a-61dc259fa9db", "evidence": "This slide is targeted at investors and partners, showing the company's technology and its applications.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:15:01.904506+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "1dbed918-5905-474c-8c04-3ba636606ba0", "evidence": "Visual split between healthy and cancer cell conditions", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:38.675+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "d534b082-76eb-47f4-b640-8a4988410764", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents the problem of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "f23101c4-32a8-4152-930d-edd35c1a515e", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents BioAtla's CAB technology and its potential to enhance clinical outcomes", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "555802a6-f553-4397-9934-b688b1464c26", "evidence": "The deck presents the limitations of current cancer therapies and the potential for CABs to transform cancer therapy", "position": 0, "objective": "What is the cost of not adopting CABs for cancer therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:28:04.831256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a three-column layout to illustrate the versatility of the CAB platform across different therapeutic mechanisms.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 5, "textChars": 313, "nDataPoints": 0, "notes": "The slide uses a three-column layout to illustrate the versatility of the CAB platform across different therapeutic mechanisms.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:38.084+00", "seconds": 2.547, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/6", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-6", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.96, "x": 0.02, "y": 0.21 }, "kind": "diagram", "text": "Three-column comparison of ADCs, Naked Antibodies IO, and Bispecific TCE", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36a1925d-45dd-47d0-a1f7-58d35f275579", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.11, "y": 0.94 }, "kind": "disclaimer", "text": "ADC – antibody drug conjugate; IO – immuno-oncology; TCE – T-cell engager", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80190d48-fb8a-4dd8-9c4f-b68cb9c48b18", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.85, "x": 0.08, "y": 0.65 }, "kind": "image", "text": "Antibody structure diagrams for each modality", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "293cb7e3-abb0-4f90-9bce-a4d2702d4c0b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "has the potential to treat multiple solid tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d633fab8-665a-4673-951e-8035eb05e5cd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Broad applicability of BioAtla's CAB platform across several antibody types", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.084+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06fd718f-9a4b-4ab5-8eec-71761ac668d9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bfea6cec-4f12-4427-81ed-a30caa25eaed", "evidence": "This slide compares different antibody types in a three-column comparison.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:15:02.080559+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "f23101c4-32a8-4152-930d-edd35c1a515e", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents BioAtla's CAB technology and its potential to enhance clinical outcomes", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "The slide uses a Gantt-style visualization to show the clinical stage of drug candidates.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 4, "textChars": 453, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to show the clinical stage of drug candidates.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:38.298+00", "seconds": 2.74, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/7", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-7", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.3, "x": 0.4, "y": 0.33 }, "kind": "chart", "text": "Gantt-style bars representing clinical trial progress for BA3011, BA3021, BA3071, and BA3182", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "192ece36-d3df-40f0-abb5-b14726678c0b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.54, "y": 0.93 }, "kind": "source-note", "text": "* Phase 2 investigator-initiated trial for Ovarian Cancer ** Indications based upon tumor target expression", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3771dec1-8aed-439c-8ac9-d1b6c4d2bb5f", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.95, "x": 0.03, "y": 0.18 }, "kind": "table", "text": "Pipeline table with columns: CAB Program, Target, Indications, IND Enabling Pre-Clinical, Phase 1 Clinical, Phase 2 Clinical, Anticipated Milestones", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3930ac4f-3d08-49e6-8a62-8638eaf229a3", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a258805f-6d35-4161-8488-ecdd42b1a329", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4761d4a7-701e-48ab-8089-1f2ac59f8c6d", "evidence": "Horizontal bars representing project timelines across clinical phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:38.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Solution", "beatId": "f23101c4-32a8-4152-930d-edd35c1a515e", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents BioAtla's CAB technology and its potential to enhance clinical outcomes", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 76, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:37.841+00", "seconds": 2.189, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/8", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-8", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.1, "x": 0.85, "y": 0.05 }, "kind": "image", "text": "Bioatla logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.841+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "530e6baf-ed87-404d-9500-71cacf59dc4c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.43, "y": 0.61 }, "kind": "paragraph", "text": "BA3011 Mecbotamab Vedotin: Sarcoma and NSCLC", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.841+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ee15ce4-62c8-408f-98ae-b5959d8347a6", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.43, "y": 0.54 }, "kind": "title", "text": "CAB-AXL-ADC Platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:37.841+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98e10638-009d-4351-93a9-47098f4059b1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7899817c-7689-45bc-86c2-bd387dfc0afa", "evidence": "This slide serves as a divider between sections, focusing on the CAB-AXL-ADC Platform.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:02.216469+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 9, "type": "resolution", "title": "The slide uses a structured list format to contrast the specific opportunity in UPS with the broader landscape of other sarcoma subtypes.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 5, "textChars": 786, "nDataPoints": 7, "notes": "The slide uses a structured list format to contrast the specific opportunity in UPS with the broader landscape of other sarcoma subtypes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.25+00", "seconds": 3.226, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/9", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-9", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.45, "x": 0.5, "y": 0.2 }, "kind": "callout", "text": "Current Treatments: Chemotherapy, chemoradiation or regional limb therapy for unresectable cases; No approved targeted therapies for UPS; Approved treatments for sarcoma ORR ~15%", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.25+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b501ef66-6953-4824-a74a-fa31b201142b", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.8, "x": 0.1, "y": 0.55 }, "kind": "list", "text": "Osteosarcoma (30% of all such malignancies); Liposarcoma (15% - 20% of all STS); Synovial sarcoma (~50% recurrence rate); Limited effective treatment options across all sarcoma subtypes", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.25+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d1000bf-f499-486b-87ea-bf7c05f1bde6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.1, "y": 0.2 }, "kind": "list", "text": "2nd most common Soft Tissue Sarcoma (STS) subtype (~15% of all STS); High-grade aggressive subtype with high recurrence rates; 3k – 4k AXL+ addressable patients per year in the U.S.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.25+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9423678f-230a-42ed-8748-896cf32d4d18", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.1, "y": 0.9 }, "kind": "source-note", "text": "Undifferentiated Pleomorphic Sarcoma - StatPearls; Annals of Oncology; Company estimates; Product USPIs; ORR, objective response rate; STS, soft tissue sarcoma; UPS, undifferentiated pleomorphic sarcoma.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.25+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "516a6ec6-5f9b-4bfb-8b86-76971a8d9e53", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Potential market opportunity in sarcoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.25+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b19866f-e478-4032-a734-6311fb6fc77a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "evidence", "title": "Includes waterfall plot for partial response and spider plot for longitudinal tumor change.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 5, "textChars": 792, "nDataPoints": 20, "notes": "Includes waterfall plot for partial response and spider plot for longitudinal tumor change.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.601+00", "seconds": 3.444, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/10", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-10", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.4, "x": 0.52, "y": 0.3 }, "kind": "chart", "text": "Spider plot of change in target lesion from baseline over time by TmPS status.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.601+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6c84a59-5db7-4cb7-b04a-738ce21f6ca9", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.3 }, "kind": "chart", "text": "Waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.601+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8f608e6-e448-46db-be91-bc695d8845c3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.11, "y": 0.9 }, "kind": "disclaimer", "text": "Notes: Multiple cycles of antineoplastic agents received prior to starting treatment with BA3011. *AXL Tumor membrane Percent Score or TmPS = % Score ≥1+; $Tissue biopsy from resection, over 1 year old prior to trial entry. 1 NED = No evidence of disease; 2 Synovial sarcoma patient delayed treatment due to unrelated SAE led to progression", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.601+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d98ac566-6192-4dda-b2e0-2db8c1eabe49", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.8 }, "kind": "list", "text": "PR was achieved in 4/7 high TmPS patients receiving the clinically-meaningful 1.8 mg/kg dose; Antitumor activity correlates with higher levels of AXL tumor membrane expression in sarcoma patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.601+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6bbfcab-2f56-46cb-b5ea-e517df821349", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory sarcoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.601+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22535516-c279-4125-9b3e-84d6f00a19ad", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cc797f63-c32c-4402-b60f-fc40d20b5f7d", "evidence": "This slide shows a waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:15:02.35454+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "The slide uses a hierarchical tree structure to map patient cohorts to their respective clinical outcomes and advancement decisions.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 4, "textChars": 969, "nDataPoints": 14, "notes": "The slide uses a hierarchical tree structure to map patient cohorts to their respective clinical outcomes and advancement decisions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:44.176+00", "seconds": 7.937, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/11", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-11", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.69, "x": 0.02, "y": 0.21 }, "kind": "diagram", "text": "Hierarchical flow from study arms to specific sarcoma subtypes and their interim results", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb64eeb2-6ae5-48ac-9f63-d7c1de7bbca6", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.78, "y": 0.365 }, "kind": "paragraph", "text": "Interim results satisfied pre-defined 'Go' criteria into part 2 of the Phase 2 BA3011 study in multiple sarcoma subtypes: UPS - clear guidance from FDA, moving into phase 2, part 2 as initial indication. Osteosarcoma, liposarcoma and synovial - pursue registration post UPS approval", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d556a9ca-df30-4c5d-bc8f-6bf32c252a08", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.11, "y": 0.93 }, "kind": "source-note", "text": "Pre-defined criteria for each subgroup up to 10 patients: 'No Go' if 0 CR/PR and PFS rate at 3 months <40%; 'Go' if ≥1 CR/PR or PFS rate at 3 months ≥40%. * As of data cut-off Oct 17, 2022; Cohorts in gray continuing enrollment until sufficient sample size is achieved. **Included in UPS cohort. BA3011 dose 1.8 mg/kg Q2W. PFS, progression-free survival; PR, partial response; UPS, undifferentiated pleomorphic sarcoma. §of 8 enrolled, 6 efficacy evaluable; 2 on-going with 1 scan.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7dff8d4d-7c7d-48b8-836c-964d4f5cbd91", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.8, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 2 Part 1 Topline Interim Analysis Results Confirm Phase 1 Signal following BA3011 in refractory sarcoma subtypes", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "793fac7d-7b8c-4d6e-abcd-7a046365dfb5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "ea02a069-cd41-4636-bb4f-5f16f4f6d2b7", "evidence": "Hierarchical flow chart mapping study arms to outcomes", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:44.176+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "process" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "evidence", "title": "Includes 'Number at Risk' table below the Kaplan-Meier plot.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 510, "nDataPoints": 12, "notes": "Includes 'Number at Risk' table below the Kaplan-Meier plot.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.732+00", "seconds": 3.369, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/12", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-12", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.45, "x": 0.03, "y": 0.215 }, "kind": "chart", "text": "Change Target Lesion From Baseline (%)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.732+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48ebe1e7-396f-4c7f-b61c-cfd264e75336", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.52, "y": 0.215 }, "kind": "chart", "text": "Progression-free Survival", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.732+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5b15d9d-f6d8-46e5-a83d-e02e67510582", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.03, "y": 0.8 }, "kind": "list", "text": "Combined Phase 1 & 2: enrolled = 10; efficacy evaluable = 8; on-going with 1 scan = 2. 4 / 8 patients achieved PRs, with an ORR of 50% and PFS rate at 3 months of 50%. Responses to BA3011 treatment are durable. Interim results satisfied criteria.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.732+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a141c8b-42f5-4609-ad94-e5da9034470e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.34, "x": 0.63, "y": 0.28 }, "kind": "table", "text": "Events n(%) 7(70.0) Median (mos) 6.8 (1.4 - NE) PFS 3mo % 50.0 (18.4, 75.3)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.732+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf560c54-2e98-48fe-88b8-0688076fc888", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Undifferentiated Pleomorphic Sarcoma (UPS): Phase 1 & 2 Change in Target Lesion and Progression Free Survival (1.8mg/kg; n=10)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.732+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0e12be1-f550-4b5e-92cb-1ec4dbea17a2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "evidence", "title": "Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 498, "nDataPoints": 20, "notes": "Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.886+00", "seconds": 3.352, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/13", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-13", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.38, "x": 0.58, "y": 0.21 }, "kind": "list", "text": "No treatment-related deaths; Few treatment-related SAEs; Very few related AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f93d540-875f-4cdb-bd5c-758ff73b2cde", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.04, "y": 0.88 }, "kind": "source-note", "text": "Interim data- Data cut-off of Oct 17, 2022. CTCAE definitions and footnotes.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f52b103-5006-4cd6-bfaf-31ea52cf41f7", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.43, "x": 0.11, "y": 0.56 }, "kind": "table", "text": "Specific adverse event grades for Constipation, Peripheral Neuropathy, and Diarrhea", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92892bb3-d756-47f3-9c8d-15f2cfc0417b", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.5, "x": 0.04, "y": 0.19 }, "kind": "table", "text": "Adverse events table comparing BA3011 and BA3011 + Nivolumab", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f846353-2e2e-4ea8-b351-c102a1b3fab4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Continued promising safety and tolerability profile in Sarcoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ad774b0-7ad6-44aa-bfa1-e3974d2494cf", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e4300c1-233b-4b7f-8c2f-74938e14766b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "ccfe9b49-4707-4b8b-b9bb-6ed766d33b47", "evidence": "Presents clinical trial safety data in a structured table and bulleted summary format.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:39.886+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "evidence-matrix" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "appendix", "function": "summarize", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 2, "textChars": 387, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:38.907+00", "seconds": 2.245, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/14", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-14", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.958, "x": 0.041, "y": 0.248 }, "kind": "list", "text": "Written feedback received from the FDA to the proposed part 2 of the Phase 2 study design, including selection of primary endpoint (ORR) and size of the study (n=80)\nFDA supportive of including a more intensive dosing arm\nProtocol being finalized post FDA written feedback\nAnticipate study enrollment commencement by year-end", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.907+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "deb1a439-31d6-4241-8c2c-8760783e2af1", "parentComponentId": null }, { "bbox": { "h": 0.033, "w": 0.713, "x": 0.033, "y": 0.083 }, "kind": "title", "text": "UPS – Part 2 of the Phase 2 study (potentially registrational)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.907+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a64454cd-832f-4d8a-94a7-8375a9e6af1f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 8, "textChars": 642, "nDataPoints": 6, "notes": "The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.983+00", "seconds": 3.303, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/15", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-15", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.9, "x": 0.03, "y": 0.76 }, "kind": "list", "text": "Target population: ~50K AXL+ addressable 2L+ patients/year in the U.S., based on AXL positivity rate of ~35%", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85943240-18b4-426d-90b9-66b3697bb40e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.03, "y": 0.8 }, "kind": "list", "text": "Internal success threshold: 2L+ ORR of ~15% - 20% (approvability bar based on precedent); 20%+ (commercially relevant) following BA3011 monotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99f643a8-0762-4a47-b546-8d7dfb9b787c", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.37, "y": 0.185 }, "kind": "metric", "text": "~200K newly diagnosed patients / year (U.S.)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31a92e30-dd12-4333-845f-e14859a405d2", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.03, "y": 0.185 }, "kind": "metric", "text": ">540K people in the U.S. living with lung cancer", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b93b7ea9-b3b0-4629-bc40-fe575f2f6d92", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.03, "y": 0.44 }, "kind": "metric", "text": "2L+ despite advances in 1L care, majority of patients progress", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8ca96d4-6ebf-4aba-b258-ee87e0c266c3", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.37, "y": 0.44 }, "kind": "metric", "text": "~75% non-squamous cell represents majority of patients", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0ce0d7b-846b-4fa4-adb4-ec253a16e057", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.8, "x": 0.11, "y": 0.95 }, "kind": "source-note", "text": "1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOC, standard of care", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "457f1342-d30e-4b32-8f70-676f26c02986", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.58, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Potential market opportunity in metastatic NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c25b97f-5606-48d3-856b-0de0e864129d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents the potential market opportunity for BioAtla's CABs", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "evidence", "title": "The chart displays maximum change from baseline for four distinct patient cohorts/scenarios.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 28, "componentCount": 3, "textChars": 237, "nDataPoints": 4, "notes": "The chart displays maximum change from baseline for four distinct patient cohorts/scenarios.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:38.826+00", "seconds": 2.098, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/16", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-16", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.48, "x": 0.06, "y": 0.295 }, "kind": "chart", "text": "Response at Variable Dosing", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7017d5b0-0555-431d-97ce-09cc095cf2db", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.63, "y": 0.42 }, "kind": "list", "text": "A partial response was achieved in the AXL-high NSCLC patient refractory to multiple chemo PKIs and pembrolizumab failure", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f98d7d7-1060-44bb-af05-f54088d76008", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory NSCLC patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:38.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97dff57b-aab3-4907-bedb-af951d599d12", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "resolution", "title": "The slide uses a process-oriented layout to describe clinical trial phases.", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 941, "nDataPoints": 2, "notes": "The slide uses a process-oriented layout to describe clinical trial phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.51+00", "seconds": 3.492, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/17", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-17", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.94, "x": 0.03, "y": 0.23 }, "kind": "diagram", "text": "Initial interim analysis, Next step, Phase 2 part 2, Endpoints", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8c6733e-1567-4890-9858-790aeab58acc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.1, "y": 0.9 }, "kind": "disclaimer", "text": "BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1. AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22fe0c91-59e3-4e8f-920e-35ce37c2e56f", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.04, "y": 0.45 }, "kind": "list", "text": "AXL+ ≥1 TmPS; Monotherapy and Combination with PD-1/L1; All patients refractory to PD-1/L1, EGFR and / or ALK inhibitors; Targeting up to ~20 pts", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a08cad7-14be-4478-a582-5db123b59368", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.74, "y": 0.45 }, "kind": "list", "text": "Primary endpoints: Confirmed ORR per RECIST v1.1, AEs or SAEs; Secondary endpoints: DOR, PFS, ORR, DCR, TTR, OS", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "281a8320-19f0-4c01-a4d8-ee5a0ce19e01", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.5, "y": 0.45 }, "kind": "list", "text": "Monotherapy (BA3011) and / or Combination (BA3011+Opdivo); n=TBD pending discussions with FDA", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "548035cb-2f39-46d3-8074-3b16e797764b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.27, "y": 0.45 }, "kind": "list", "text": "If definitive, move into part 2; Ability to continue interim enrollment up to ~40 patients, if desired", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5dc5e39a-5bad-4304-a54d-1f2049be988d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 2 study design with BA3011 (Mecbotamab Vedotin) in refractory NSCLC patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.51+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c0fd28d-6110-423e-a873-7ba1d59081d0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "evidence", "title": "Data cut-off Oct 28, 2022. Includes definitions for W/D, NSQ, SQ, and response markers.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 505, "nDataPoints": 11, "notes": "Data cut-off Oct 28, 2022. Includes definitions for W/D, NSQ, SQ, and response markers.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:44.285+00", "seconds": 7.255, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/18", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-18", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.65, "x": 0.28, "y": 0.25 }, "kind": "chart", "text": "ORR (%) by patient cohort: NSQ+SQ (36%), All NSQ (42%), NSQ monotherapy (50%), NSQ mono PD-1 Failure (57%), NSQ BA3011 + nivolumab (25%), SQ (0%)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c39bdfdb-2352-49c0-abc7-b6e9ce1b97cf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.35, "y": 0.87 }, "kind": "source-note", "text": "W/D - withdrew; NSQ - non-squamous; SQ - squamous. Responses include 4 partial responses (*) and one complete response (**)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e929445b-952b-4029-9e27-a9a780d4bf3f", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.03, "y": 0.29 }, "kind": "table", "text": "Enrolled: 24; Dosed / 0 scan: 6 (3 combo); Not yet dosed: 2; W/D consent: 2; Efficacy evaluable: 14", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9caa38d6-0bd6-4ad5-8bea-777144fc42ba", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.03, "y": 0.15 }, "kind": "title", "text": "supports advancing preparations for part 2 in refractory NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f59e19f6-2f2c-41bc-90b2-edf08034affd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 2 part 1 BA3011 NSCLC initial interim analysis confirms Phase 1 signal", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1add181b-1086-41e8-ab67-42771b75dcf4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "09b773e7-c2fb-4dce-93c1-8683ed154e8c", "evidence": "chart/bar-vertical: ORR (%) by patient cohort: NSQ+SQ (36%), All NSQ (42%), NSQ monotherapy (50%), NSQ mono PD-1 Failure (57%), NSQ BA3011 + nivolumab (25%), SQ (0%)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:36:36.219388+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "evidence", "title": "Waterfall plot showing clinical response (PD, SD, PR, CR) for patients treated with BA3011.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 334, "nDataPoints": 12, "notes": "Waterfall plot showing clinical response (PD, SD, PR, CR) for patients treated with BA3011.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.429+00", "seconds": 2.361, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/19", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-19", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.65, "x": 0.13, "y": 0.23 }, "kind": "chart", "text": "Waterfall plot of % change in sum of target lesions", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.429+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "344fc41a-551a-4bb4-a939-589eca5406c1", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.1, "x": 0.18, "y": 0.72 }, "kind": "legend", "text": "---Monotherapy ---Combination", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.429+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a65e470-d355-4577-bb9b-1c6e7756d283", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.16, "y": 0.85 }, "kind": "paragraph", "text": "TmPS range 1% - 100%. Average prior lines of therapy = 3. All patients were PD-1 failure with the exception of 1 NSQ patient who failed EGFR treatment.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.429+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb1a9723-a7db-430b-b970-edbb0e1c622c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.14 }, "kind": "paragraph", "text": "Non-Squamous patients - Phase 2 only 1.8mg/kg Q2W", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.429+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f02760b4-ce92-4078-bf3a-07c31fd1c816", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "BA3011: Best Response in Phase 2 Non-Squamous Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.429+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86173a4d-d220-49be-aa71-74eb0b7b9811", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f0f6a059-c21d-467b-af9c-27e08496b7ec", "evidence": "chart/waterfall: Waterfall plot of % change in sum of target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:36:36.29041+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "evidence", "title": "Data presented in a table format comparing BA3011 (N=13) and BA3011 + Opdivo (N=9).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 495, "nDataPoints": 16, "notes": "Data presented in a table format comparing BA3011 (N=13) and BA3011 + Opdivo (N=9).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.066+00", "seconds": 2.96, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/20", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-20", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.38, "x": 0.58, "y": 0.23 }, "kind": "list", "text": "No treatment-related deaths; Few treatment-related SAEs; Few AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dea8064b-d4ff-4135-8be2-13d88313cdd9", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.12, "y": 0.88 }, "kind": "paragraph", "text": "Low-grade constipation observed is consistent with baseline levels seen in advanced cancer patients", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "19c131d3-19b4-43d1-a1eb-e99afa8e1a2d", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.65, "x": 0.12, "y": 0.92 }, "kind": "source-note", "text": "Interim data- Data cut-off of Oct 25, 2022. CTCAE definitions and footnotes.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a421006-42eb-4bb1-b4d6-c3b040cfe8c4", "parentComponentId": null }, { "bbox": { "h": 0.72, "w": 0.48, "x": 0.04, "y": 0.21 }, "kind": "table", "text": "Adverse events table comparing BA3011 and BA3011 + Opdivo", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04f8033e-fa8d-44fd-97d7-7294b327e88c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1fb7a1da-5293-484b-acef-e0d213722c87", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.68, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Promising safety and tolerability profile emerging in NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.066+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0bb9d97a-b89f-403e-a217-65de681d9e60", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3", "matchId": "9a9413e2-d8d9-483a-a227-294d3af4f950", "beatType": null, "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 10, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732", "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs", "position": 1, "objective": "What are the key results and milestones for BioAtla's CABs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:04.869694+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 84, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:39.585+00", "seconds": 2.397, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/21", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-21", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.12, "x": 0.85, "y": 0.06 }, "kind": "image", "text": "BioAtla logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d66f35f1-438f-40aa-84d2-8458565ada2b", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.45, "x": 0.432, "y": 0.618 }, "kind": "paragraph", "text": "BA3021 Ozuriftamab Vedotin – NSCLC, Melanoma, SSCHN", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fd6eeab-f209-47fc-912f-ea69861b3a7f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.255, "x": 0.432, "y": 0.548 }, "kind": "title", "text": "CAB-ROR2-ADC Platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:39.585+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c234345c-2117-4ff7-abf6-6ef91e432526", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "resolution", "title": "The slide uses a grid of metrics to define the addressable market and clinical success thresholds.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 84, "componentCount": 8, "textChars": 748, "nDataPoints": 8, "notes": "The slide uses a grid of metrics to define the addressable market and clinical success thresholds.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.302+00", "seconds": 3.101, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/22", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-22", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.11, "y": 0.95 }, "kind": "disclaimer", "text": "1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOC, standard of care.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb55100c-4a3c-4ce7-a8a8-81747a445abd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.71, "y": 0.25 }, "kind": "list", "text": "Available Treatment: 1L: Chemo + ICI 50% ORR; 2L+: SOC 10% - 20% ORR", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf41feb7-0eea-44b8-a1df-1cc624df0c34", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.94, "x": 0.03, "y": 0.76 }, "kind": "list", "text": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%. Internal success threshold: 2L+ ORR of ~15% - 20% (approvability bar based on precedent); 20%+ (commercially relevant) following BA3011 monotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2262ce9-9228-4113-bd57-7b7ae938a2ee", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.33, "x": 0.03, "y": 0.442 }, "kind": "metric", "text": "2L+ despite advances in 1L care, majority of patients progress", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87fc9fc6-86bf-42af-bffc-b3b3eedcb3e4", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.33, "x": 0.03, "y": 0.188 }, "kind": "metric", "text": ">540K people in the U.S. living with lung cancer", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1990a92-7bca-4e9a-85e4-8e9939f69376", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.33, "x": 0.37, "y": 0.442 }, "kind": "metric", "text": "~75% non-squamous cell represents majority of patients", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7658d20-7615-4cd2-b2e4-4dc4a268ad11", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.33, "x": 0.37, "y": 0.188 }, "kind": "metric", "text": "~200K newly diagnosed patients / year (U.S.) – majority advanced / metastatic", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fef1bd36-9d19-4d71-b314-4c94f4d49c84", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.58, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Potential market opportunity in metastatic NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b5ae4df-caae-42eb-941a-b199ebc0859f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "e9f27a62-e4a4-4938-af0c-d29e84fd6ebf", "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:57:48.048382+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b0d509be-e63f-4ab7-994f-3c2a07941549", "evidence": "Target population: ~40K ROR2+ addressable 2L+ patients/year in the U.S., based on ROR2 positivity rate of ~30%.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:57:48.007293+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "evidence", "title": "The chart is a waterfall plot showing percentage change in tumor size for individual patients.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 4, "textChars": 302, "nDataPoints": 6, "notes": "The chart is a waterfall plot showing percentage change in tumor size for individual patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:43.171+00", "seconds": 5.792, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/23", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-23", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.45, "x": 0.13, "y": 0.25 }, "kind": "chart", "text": "Waterfall plot of tumor shrinkage", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:43.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae6fe209-0a11-43dd-b9e1-3a44570f9adb", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.72, "y": 0.4 }, "kind": "list", "text": "Two out of three ROR2+ patients had a partial response following ozuriftamab vedotin treatment", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:43.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "930aca7c-7ad9-432a-a074-a2495c126461", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.15, "y": 0.85 }, "kind": "source-note", "text": "Note: Not Evaluable (Strong, extensive fibroblastic stromal positivity reported)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:43.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f625b14c-d399-4f39-868d-40d5db1f89cc", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Encouraging Phase 1 results with BA3021 (Ozuriftamab Vedotin) in refractory patients with NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:43.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56904944-6da5-456a-afe4-18dbdfdd3e6f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "61996e84-872f-4056-9bda-3c182221e51f", "evidence": "chart/waterfall: Waterfall plot of tumor shrinkage", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:36:36.358062+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "resolution", "title": "The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population sizing.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 8, "textChars": 686, "nDataPoints": 6, "notes": "The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population sizing.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.921+00", "seconds": 3.255, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/24", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-24", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.03, "y": 0.76 }, "kind": "list", "text": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~10%. Internal success threshold: 2L+ ORR of ~20% (approvability bar based on precedent); 25%+ (commercially relevant) following BA3011 monotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40c8efc5-fcbb-472c-af02-28825317ab37", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.35, "y": 0.195 }, "kind": "metric", "text": "~100K newly diagnosed invasive cases / year (U.S.)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1cca8bf7-8b2b-4f91-b72c-fd25d68b3d13", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.03, "y": 0.195 }, "kind": "metric", "text": "~1.3MM people in the U.S. living with melanoma", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4af9be7-0327-4104-abba-ed70781f355e", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.03, "y": 0.45 }, "kind": "metric", "text": "~50% do not respond to PD-1 therapy in 1L setting", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa5a6c0e-136a-479d-bb8f-f33422107f1e", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.35, "y": 0.45 }, "kind": "metric", "text": "30-40% initial responders progress", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0074be9-c23d-492d-8f38-ab67862851d4", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.7, "y": 0.2 }, "kind": "paragraph", "text": "Available Treatment: 1L: ICIs 33% - 50% ORR; (BRAF / Mek inhibitors for BRAF+). 2L+: ICIs 9% - 28% ORR (mono – combo, respectively)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "107af039-baba-4d2c-b9da-9c733b6c4527", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Clarivate, Disease Landscape and Forecast: Malignant Melanoma (2022)...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eebf0138-41b7-4992-94b0-df227759fd39", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "Potential market opportunity in metastatic melanoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e18bec87-0f5c-4223-b2b2-62fc43b2bad8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "0959c604-a95b-4595-bb21-1704568041be", "evidence": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:14:57.505202+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cc5bc808-c6df-42f4-afce-74ffcd8de777", "evidence": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:14:57.466583+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "4ea6b357-7202-47b7-ba92-38f2187bd062", "evidence": "Quantifies total addressable population and specific sub-segments for a drug candidate.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:40.921+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "market-sizing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "evidence", "title": "The chart displays longitudinal data for two specific patients, showing sustained complete response.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 6, "textChars": 370, "nDataPoints": 2, "notes": "The chart displays longitudinal data for two specific patients, showing sustained complete response.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.483+00", "seconds": 3.582, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/25", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-25", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.6, "x": 0.03, "y": 0.23 }, "kind": "chart", "text": "Longitudinal % change in target lesions over time for two patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1588c9f-3286-4cef-906a-dda628e9ce50", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.68, "y": 0.25 }, "kind": "list", "text": "Phase 1 Patient Details: Prior treatment failure, clearance of metastases, continued CR for 2+ years", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2be06d50-f1a8-49b0-a556-c134a82bbbd5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.68, "y": 0.65 }, "kind": "list", "text": "Phase 2 Patient Details: Prior treatment failure, Complete Response on 1st scan", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc5299d2-0c95-4ed3-9c20-2780e1600605", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.05, "x": 0.11, "y": 0.94 }, "kind": "source-note", "text": "Data on file.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d50dd08-eedc-473e-8d3b-a0f1c7e0d19c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Complete Response Observed in 2 out of 2 ROR2+ Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a1d7608-6f6c-434b-9c37-8bfa94521804", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 1 & 2 Results in Stage IV Multi-Refractory Melanoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c39a79f0-0046-40ab-b0fb-4400b59cca67", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "resolution", "title": "The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 87, "componentCount": 9, "textChars": 714, "nDataPoints": 7, "notes": "The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.183+00", "seconds": 3.274, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/26", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-26", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.8, "x": 0.04, "y": 0.79 }, "kind": "list", "text": "Internal success threshold: 2L+ ORR of ~15% (approvability bar based on precedent); 15%+ (commercially relevant) following BA3011 monotherapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c24f4d7-7327-409c-a9fd-27a9592d01bf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.04, "y": 0.75 }, "kind": "list", "text": "Target population: ~12K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~60%", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49d59678-d257-47a2-8363-458b97fa1b90", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.03, "y": 0.184 }, "kind": "metric", "text": ">400K people living with head and neck cancer (U.S.)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "392fc958-cd7b-469c-bd37-010239b1d964", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.35, "y": 0.44 }, "kind": "metric", "text": "2L+ limited effective options post 1L", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "838e5037-6c1a-4aba-816f-04dae14564b6", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.35, "y": 0.184 }, "kind": "metric", "text": "~66K newly diagnosed cases / year (U.S.)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce24f93d-11a4-477f-9d10-13c25735c7d4", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.03, "y": 0.44 }, "kind": "metric", "text": "~50% with locally advanced disease develop recurrent or refractory disease", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa86f6bb-223d-4512-8545-ef20db63bfea", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.22 }, "kind": "paragraph", "text": "Available Treatment: 1L: Pembro, cetuximab, platinum 36% ORR; 2L+: ICIs 13% - 16% ORR", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d709be97-5b3f-4b7b-9d63-343d4cdf3543", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.11, "y": 0.88 }, "kind": "source-note", "text": "Clarivate, Disease Landscape and Forecast: SCCHN (2022); Argiris A, et al.(2017); Future Oncology, Jan. 2019; Ketruda USPI; Opdivo USPI.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae4be0f9-1c89-4a60-8293-5eb4baf89e76", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Potential market opportunity in SCCHN", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc107767-f4e6-4baf-b249-212b21eeba81", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "evidence", "title": "The slide uses a table to present clinical outcomes (PR/CR) for specific tumor types, supporting the 'first-in-class' claim.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 3, "textChars": 324, "nDataPoints": 4, "notes": "The slide uses a table to present clinical outcomes (PR/CR) for specific tumor types, supporting the 'first-in-class' claim.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.642+00", "seconds": 2.692, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/27", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-27", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.8 }, "kind": "paragraph", "text": "No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is a first-in-class therapy across multiple tumor types", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.642+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5f2cc95-d119-4a7e-b586-92a0f308e024", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.94, "x": 0.03, "y": 0.238 }, "kind": "table", "text": "ROR2+ Tumor Types: NSCLC, Melanoma, SCCHN. Results: PR in 2/3 patients, CR in 1/1 patient, PR in 1/1 patient.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.642+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7eeaee4f-fdae-4017-b134-a9f2b0245909", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 1 results with BA3021 support advancing into Phase 2 in multiple indications", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.642+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d295423a-478a-49ad-a2e9-a5ccb8df16de", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "SCQA Framework", "slug": "scqa-framework", "status": "active", "bestFor": null, "canonId": "019dd956-7bcb-763f-bdf6-1dfedf3bd36c", "version": 1, "bodyDocId": "019df22a-a0b0-719e-937e-2ac31e53d32c", "description": "Situation, Complication, Question, Answer - structured problem framing", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "abe9e13d-d8a1-4948-bcba-54719354c2fe", "evidence": "No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is a first-in-class therapy across multiple tumor types", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:14:57.642533+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "resolution", "title": "The slide uses a process-flow layout to describe clinical trial progression.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 8, "textChars": 1075, "nDataPoints": 4, "notes": "The slide uses a process-flow layout to describe clinical trial progression.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.435+00", "seconds": 3.462, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/28", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-28", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.94, "x": 0.03, "y": 0.185 }, "kind": "diagram", "text": "Initial interim analysis, Next step, Phase 2 part 2, Endpoints", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e03ffaa-f8b5-4ae7-a148-268de13cebf2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.1, "y": 0.91 }, "kind": "disclaimer", "text": "BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1. AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "192ba4b6-b24c-4bf8-8aaa-0fe6f3ca7829", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.75, "y": 0.37 }, "kind": "list", "text": "Primary endpoints: Confirmed ORR per RECIST v1.1, AEs or SAEs; Secondary endpoints: DOR, PFS, ORR, DCR, TTR, OS, tumor size", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8820197e-bb84-4518-ab55-b7698d367918", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.05, "y": 0.37 }, "kind": "list", "text": "ROR2+ ≥1 TmPS; Melanoma: PD1 failure; NSCLC: PD1, EGFR or ALK failure; SCCHN: PD1 alone or in combination w/ platinum failure; Monotherapy and Combination with PD-1/L1; Targeting up to ~20 pts", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee2745bf-b966-4b55-bd27-9ed454e1e693", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.27, "y": 0.37 }, "kind": "paragraph", "text": "If definitive, move into part 2; Ability to continue enrollment up to ~40 patients, if desired", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1bfc8ec6-8540-4783-a963-44c355021252", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.5, "y": 0.37 }, "kind": "paragraph", "text": "Monotherapy (BA3021) and / or Combination(BA3021+Opdivo); n=TBD pending discussions with FDA", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5d44ff7-3b58-4599-983a-164cf2a20d28", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.03, "y": 0.83 }, "kind": "source-note", "text": "*To date, CR on first scan (3 doses), n=1", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a06f277-a155-42b4-bd69-5cd703380e3f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: NSCLC, Melanoma, and SCCHN", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12be39b9-e902-480d-970f-a230288cd872", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 65, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.147+00", "seconds": 3.109, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/29", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-29", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.12, "x": 0.85, "y": 0.06 }, "kind": "image", "text": "bioatla", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c29d4ad-cfb3-4345-a5b4-22a339d0f90d", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.475, "x": 0.433, "y": 0.545 }, "kind": "title", "text": "Naked Antibody IO Platform: CTLA-4 (BA3071) – Basket Trial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55bb9b51-dfeb-4a8e-972d-55a523565257", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "setup", "title": "The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 781, "nDataPoints": 9, "notes": "The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.931+00", "seconds": 3.844, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/30", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-30", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.38, "x": 0.03, "y": 0.215 }, "kind": "callout", "text": "Research demonstrates challenges and opportunity in combining two Immune Checkpoint Inhibitors. Improves efficacy, but increases adverse events. Greater % of patients discontinue therapy relative to monotherapy.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b3b5818-1d25-41dd-9d04-a71436568d87", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.5, "x": 0.46, "y": 0.54 }, "kind": "chart", "text": "NHP study GI symptoms dot plot comparing Nivo + Ipi vs Nivo + BA3071", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eea8d45f-38a6-44e8-9427-399ea9ccfdef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.38, "x": 0.03, "y": 0.56 }, "kind": "paragraph", "text": "In NHP study, BA3071 achieved similar exposure levels to Ipi analog with significantly less toxicity in combination with nivo.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aced4d9e-39f1-4261-a174-d547731cfb97", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.11, "y": 0.88 }, "kind": "source-note", "text": "*Larkin et al., New Eng. J. Med.,373: 23-34, 2015 **Chang et al., PNAS 118 (9): 1-10, 2021", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb32f19c-55f7-4239-9e39-ab277a78914d", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.5, "x": 0.46, "y": 0.24 }, "kind": "table", "text": "Clinical Endpoint, Nivolumab (PD-1), Nivolumab (PD-1) + Ipilimumab (CTLA4). Progression Free Survival, 6.9 months, 11.5 months. Grade 3 or 4 Adverse Events, 16.3%, 55.0%. Discontinued Treatment, 7.7%, 36.4%.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad2d227b-2a59-4da8-8d8e-edb87dbbe2ea", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.5, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Best-in-class and potential for disruption of the I/O Market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba97ce5b-bf73-434f-b9c6-16e1b279fc11", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "BA3071 (CAB-CTLA-4)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "603054d4-d4a2-49d8-b334-363e9404ed00", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "621bcb66-5ff1-4438-b622-c7f5165c02b7", "evidence": "Table comparing clinical endpoints of two drug regimens", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:41.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "resolution", "title": "The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 444, "nDataPoints": 14, "notes": "The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.698+00", "seconds": 3.329, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/31", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-31", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.5, "x": 0.05, "y": 0.22 }, "kind": "chart", "text": "Dose escalation timeline for BA3071 cohorts", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8cfb3948-020f-49c8-bcc0-0f966800106d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.18, "y": 0.79 }, "kind": "list", "text": "Objectives: Determine Phase 2 dose and MTD; Characterize safety and clinical activity; Characterize PK, ADA and biomarkers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14c7ea35-198e-4dbe-980b-bf87d39ce73b", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.7, "y": 0.36 }, "kind": "list", "text": "Possible Phase 2 Dose Expansion Cohorts: RCC, Melanoma, NSCLC, SCLC, Bladder, Gastric, aHCC, Cervical (all n=40)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c9c2605-8f46-4a30-8501-47108e8c7ccc", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.14 }, "kind": "paragraph", "text": "in tumors known to be responsive to CTLA-4 treatment", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ae0e9fc-c38e-4467-9ef9-6a068b498479", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.11, "y": 0.94 }, "kind": "source-note", "text": "*Dose equivalent to approved ipilimumab dose (1 mg/kg)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55851263-5691-4dd7-a7bc-8f7040ba0bd6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 1/2 trial design for CAB-CTLA-4 Naked Antibody (BA3071)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d85c2443-72f7-4749-8497-67ac3c03456f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "472d08e7-1180-40a5-aa8c-765a5a10505f", "evidence": "The timeline visualization of trial cohorts functions as a Gantt chart for clinical development.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:41.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 71, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.571+00", "seconds": 2.168, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/32", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-32", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.12, "x": 0.85, "y": 0.06 }, "kind": "image", "text": "bioatla", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54993cea-a9c4-4b09-bc63-c7e8c9dc30df", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.4, "x": 0.432, "y": 0.615 }, "kind": "paragraph", "text": "CAB-EpCAM x CAB-CD3 (BA3182) – Adenocarcinoma", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68910c31-2e75-474f-a6e9-a6fb38ab82fa", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.432, "y": 0.545 }, "kind": "title", "text": "Bispecific Platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2a60e12-dc2f-40d5-ba0b-115f4bd04115", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "resolution", "title": "Uses a before-after-bridge style framing (problem on left, solution/results on right).", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 7, "textChars": 871, "nDataPoints": 12, "notes": "Uses a before-after-bridge style framing (problem on left, solution/results on right).", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:47.043+00", "seconds": 8.62, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/33", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-33", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.4, "x": 0.06, "y": 0.62 }, "kind": "chart", "text": "Tumor shrinkage", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c05469d-c8e4-4aba-9fdd-8f2e9d3336dd", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.38, "x": 0.06, "y": 0.185 }, "kind": "diagram", "text": "EpCAM expressed on normal epithelial cells and overexpressed in a wide range of tumors (adenocarcinoma). CD3-bispecifics have demonstrated beneficial effects but hampered by dose-limiting toxicity, namely, cytokine release syndrome (CRS)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0779645f-ee55-4e1a-803f-0f8f4f4838c4", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.53, "y": 0.18 }, "kind": "list", "text": "BA3182 exhibits efficient tumor shrinkage with superior safety profile. In non-GLP and GLP tox studies in NHP, dual selection results in high selectivity. 160-fold TI increase. MTD not reached. No Cytokine release observed.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dbdf3803-a43e-45ba-9df7-bd12a1ad94cc", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.13, "y": 0.92 }, "kind": "source-note", "text": "MiXeno Model with HCT116 = Colorectal Cancer Cell Line; 1mg/kg twice/week in mice; Single Dose - non-GLP Toxicity Study; WT = wild type; MTD = Maximum Tolerated Dose; TI = Therapeutic Index", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d86fb88-1fd3-47ea-8444-834fbd51f033", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.53, "y": 0.62 }, "kind": "table", "text": "Safety Profile comparison of WT-EpCAM x WT-CD3 vs CAB-EpCAM x CAB-CD3 (BA3182)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9cf040b-8fb0-408f-adde-40a2123d3e06", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Significant opportunity for safe and effective EpCAM x CD3 bispecific", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cc9e55f-85fb-4f2e-bab0-148844060e53", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "BA3182 – CAB-EpCAM x CAB-CD3 Bispecific T-Cell Engager (TCE)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b8177d9-20c4-4a60-9598-6892b35ea1ba", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b88141b5-d8d7-45a8-b2e4-eb2c57a0c0d9", "evidence": "The slide contrasts the problem of CRS/toxicity in standard bispecifics with the solution/results of BA3182.", "framework": null, "confidence": 0.85, "extraction": { "at": "2026-05-02 12:19:47.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "before-after-bridge" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "setup", "title": "The slide uses a process flow diagram to illustrate clinical trial dose escalation cohorts.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 835, "nDataPoints": 4, "notes": "The slide uses a process flow diagram to illustrate clinical trial dose escalation cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:45.573+00", "seconds": 6.908, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/34", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-34", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.6, "x": 0.03, "y": 0.2 }, "kind": "diagram", "text": "Group A, B, and C trial flow", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c43de42-becb-4ff2-9b28-29f8b1fd8a26", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.17, "y": 0.75 }, "kind": "list", "text": "DL1A: MABEL based starting dose 0.04 µg/kg; The actual number of dose levels depends on the dose level at which the first Grade ≥2 AE or DLT occurs; MTD: Maximum tolerated dose; PAD: Pharmacologically active dose; Dosing schedule: every week (QW) initially, every two weeks (Q2W) may also be explored; PDL1C: first priming dose level; PDLxC: final priming dose level", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1377383-9903-4990-ae2e-75484a2ccfd6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.65, "y": 0.55 }, "kind": "paragraph", "text": "Part 2: Open-label study to evaluate the efficacy and safety of BA3182 in patients with advanced adenocarcinoma who have a qualifying EpCAM-expressing tumor membrane percent score (TmPS).", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f363aec-cf82-4326-bce3-2442abbe1305", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.65, "y": 0.2 }, "kind": "paragraph", "text": "Part 1: Up to 128 patients with advanced adenocarcinoma. 8 patients in the accelerated titration. 60 in each of the 2-treatment schedules for 10 planned standard titration dose levels.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebd879e8-1ccf-4d15-9a09-7e7788d47bd9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Phase 1/2 trial design for CAB-EpCAM x CAB-CD3 Bispecific TCE (BA3182)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a86c8c92-4261-43c8-87c7-0e12f5297607", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "9c6f5b16-d8ce-45d2-b83f-f6884e5cd49a", "evidence": "Flowchart showing dose escalation steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:19:45.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "resolution", "title": "The slide uses a table-based timeline format to map specific clinical trial phases to programs and indications.", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 34, "componentCount": 4, "textChars": 306, "nDataPoints": 0, "notes": "The slide uses a table-based timeline format to map specific clinical trial phases to programs and indications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:41.731+00", "seconds": 2.699, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/35", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-35", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": null, "kind": "framework", "text": "Timeline of clinical milestones", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ec130969-0147-4273-ba0e-dc954306e5d1", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.1, "y": 0.94 }, "kind": "source-note", "text": "*Phase 2 Investigator-initiated trial combination with PD-1 (n=60) in platinum failure patients. Initial sites activated. **Anticipated indications based upon tumor target expression.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81b452ce-2b94-4f6a-81e5-fbe38fead2e2", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.94, "x": 0.03, "y": 0.18 }, "kind": "table", "text": "Program and Indication milestone mapping for 2022", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac21a640-6292-491b-a8d5-d271387c8e32", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.5, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "A number of key upcoming milestones in 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c752cb39-0adb-4d3e-b5fe-998c5c40c1e6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "adf2e475-f229-469c-baff-98b6802b4643", "evidence": "The slide maps specific activities (milestones) against a time axis (1H/2H 2022).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:19:41.731+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 36, "type": "setup", "title": "The slide uses a linked-circle diagram to represent the company's key pillars.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 3, "textChars": 269, "nDataPoints": 1, "notes": "The slide uses a linked-circle diagram to represent the company's key pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:44.121+00", "seconds": 5.086, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/36", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-36", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "Four linked circles containing key company highlights: Proprietary technology, Two Phase 2 CAB-ADCs, Diversified pipeline, Strong cash position.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.121+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10dff608-32c4-4827-bee3-fb40f99f3129", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.78, "y": 0.45 }, "kind": "metric", "text": "$178.1MM", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.121+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32ed78fe-58c6-400f-a78b-97f9a372242e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.121+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf4b445e-53ea-41e6-89e6-14a0b1344bfc", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "db7bc366-f648-4bbc-9263-e9459d39e9f4", "evidence": "This slide serves as an executive summary with key company highlights.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:14:59.192856+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "5bd3611f-c677-45a5-87da-b66e8fc8ec7c", "evidence": "The linked circular diagram suggests a continuous, reinforcing process.", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 12:19:44.121+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "flywheel" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "appendix", "function": "appendix", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 15, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:40.973+00", "seconds": 1.878, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/37", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-37", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.115, "x": 0.85, "y": 0.062 }, "kind": "image", "text": "bioatla", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afaa77fe-68bf-4037-8bde-22e26b106fdf", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.12, "x": 0.432, "y": 0.548 }, "kind": "title", "text": "APPENDIX", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:40.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ab52e01-fe62-44c0-908d-9b475cbc062d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "setup", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 13, "textChars": 239, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:44.085+00", "seconds": 4.531, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/38", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-38", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.23, "w": 0.115, "x": 0.127, "y": 0.6 }, "kind": "image", "text": "James Allison, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25595025-9ad9-4690-92ca-1f7e9a9a4f5b", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.525, "y": 0.188 }, "kind": "image", "text": "Sylvia McBrinn", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2bb7d39f-7b85-49ea-ab5d-be544a01dc73", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.5, "y": 0.79 }, "kind": "image", "text": "Geoffrey Wahl, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34444eaf-f1eb-48fa-b818-d19cf9b81211", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.137, "y": 0.358 }, "kind": "image", "text": "Scott Smith", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55e94422-6a02-4408-96cd-0225d090ab35", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.66, "y": 0.358 }, "kind": "image", "text": "Eddie Williams", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6586fd26-471d-4006-89a1-a8db02113518", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.27, "y": 0.79 }, "kind": "image", "text": "Padmanee Sharma, MD, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67bf4528-6499-4d27-9476-ce7290166fb2", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.395, "y": 0.6 }, "kind": "image", "text": "Lawrence Fong, MD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f0bf77d-e9db-48d4-be54-5eecc98b4ae7", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.663, "y": 0.6 }, "kind": "image", "text": "Michael Manyak, MD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b1ed982-1459-44a3-9693-c59bf15c30ff", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.287, "y": 0.188 }, "kind": "image", "text": "Mary Ann Gray, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8cbd9a66-eb5a-4678-9b9f-0d9c7cd95129", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.743, "y": 0.188 }, "kind": "image", "text": "Susan Moran, MD, MSCE", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a03ffa20-618a-4b65-82e5-d97ed29a8e8e", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.049, "y": 0.188 }, "kind": "image", "text": "Jay Short, PhD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9190044-76fc-4c90-9e24-ea3b3bd068c4", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.115, "x": 0.395, "y": 0.358 }, "kind": "image", "text": "Lawrence Steinman, MD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f50d4a9a-b053-45e1-98a1-792ebebb28d6", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.392, "x": 0.034, "y": 0.085 }, "kind": "title", "text": "Board of Directors and Advisors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:44.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9fd2c4a-6c9f-4b1c-ba57-e7819adf0b68", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "evidence", "title": "Includes a Kaplan-Meier survival curve and a summary table of clinical outcomes.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 627, "nDataPoints": 6, "notes": "Includes a Kaplan-Meier survival curve and a summary table of clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:42.08+00", "seconds": 2.516, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/39", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-39", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.63, "x": 0.21, "y": 0.2 }, "kind": "chart", "text": "Kaplan-Meier plot of Progress-Free Survival Probability over Months from First Dose", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.08+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58923be7-d448-4733-b1ad-452092c78be9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.82 }, "kind": "list", "text": "Of 6 patients enrolled, PFS rate at 3 months was 66.7%\nInterim results satisfied the pre-defined Go criteria of osteosarcoma cohort into part 2 of the Phase 2 study", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.08+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a153cc4e-a0ef-4858-b684-80ee595ace59", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.11, "y": 0.92 }, "kind": "source-note", "text": "Interim data- Data cut-off of Oct 17, 2022. Recent independent phase 2 study demonstrated placebo PFS rate at 2 months for 1st and 2nd line metastatic osteosarcoma of ~0% (www.thelancet.com/oncology Vol 20 January 2019)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.08+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5fa7890-0698-41e0-99fe-38ce27cb9a82", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.46, "x": 0.34, "y": 0.26 }, "kind": "table", "text": "Events n(%), Median (mos) (95% CI), PFS 3mo % (95%CI) for All Patients", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.08+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b636b36-6083-4299-9503-2de175bb1b15", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Osteosarcoma: Phase 2 Change in Target Lesion and Progression Free Survival (1.8mg/kg; n=6)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.08+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c246405d-d9bb-47db-895c-776566398464", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 40, "type": "evidence", "title": "Includes Kaplan-Meier plots with embedded data tables for two distinct patient cohorts.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 7, "textChars": 366, "nDataPoints": 12, "notes": "Includes Kaplan-Meier plots with embedded data tables for two distinct patient cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:19:42.739+00", "seconds": 3.036, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/40", "deck": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0", "deckAnchor": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-40", "deckJson": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.45, "x": 0.52, "y": 0.185 }, "kind": "chart", "text": "Synovial Sarcoma Kaplan-Meier plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3de231b5-f4e5-4a36-af5e-fab72d8abd80", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.45, "x": 0.03, "y": 0.185 }, "kind": "chart", "text": "Liposarcoma Kaplan-Meier plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5da19e3-c34b-4131-a965-f58dd2004ce3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.1, "y": 0.84 }, "kind": "paragraph", "text": "Interim results satisfied the pre-defined Go criteria of liposarcoma and synovial sarcoma cohorts into part 2 of the Phase 2 study.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55408bab-b67b-424a-80e5-907dfe077b54", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.12, "y": 0.94 }, "kind": "source-note", "text": "Interim data- Data cut-off of Oct 17, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e359a8b4-b272-4c40-8723-eee028150b67", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.185, "y": 0.3 }, "kind": "table", "text": "Liposarcoma cohort data table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99a8678e-4def-4718-899d-383065486809", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.65, "y": 0.3 }, "kind": "table", "text": "Synovial Sarcoma cohort data table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af80f8f0-06cf-461d-bfa2-9df3baf187e2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "Liposarcoma and Synovial sarcoma: Phase 2 Progression Free Survival", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:19:42.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8810e99-fe64-40e5-bb81-13a3bfe75253", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 3, "to": 5, "label": "Problem", "description": "The deck presents the problem of current cancer therapies and the potential for CABs to transform cancer therapy" }, { "from": 5, "to": 7, "label": "Solution", "description": "The deck presents BioAtla's CAB technology and its potential to enhance clinical outcomes" }, { "from": 10, "to": 20, "label": "Traction", "description": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs" }, { "from": 9, "to": 15, "label": "Market Size", "description": "The deck presents the potential market opportunity for BioAtla's CABs" } ], "loops": [ { "from": 3, "to": 5, "label": "Cost Of Inaction", "description": "What is the cost of not adopting CABs for cancer therapy?" }, { "from": 10, "to": 20, "label": "Quick Win Big Bet", "description": "What are the key results and milestones for BioAtla's CABs?" } ] }